YIH
ITCI

Y-Intercept (HK)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Y-Intercept (HK)’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,525
Closed -$545K – 1688
2024
Q4 		$545K Sell
6,525
-7,126
-52% -$586K 0.04% 686
2024
Q3 		$999K Sell
13,651
-62,349
-82% -$4.69M 0.06% 449
2024
Q2 		$5.21M Buy
76,000
+59,696
+366% +$4.14M 0.29% 62
2024
Q1 		$1.13M Buy
+16,304
New +$1.12M 0.09% 338
2023
Q2 		– Sell
-25,982
Closed -$1.41M – 1805
2023
Q1 		$1.41M Buy
25,982
+6,739
+35% +$326K 0.16% 168
2022
Q4 		$1.02M Buy
+19,243
New +$964K 0.15% 195
2022
Q3 		– Sell
-3,593
Closed -$205K – 1334
2022
Q2 		$205K Sell
3,593
-756
-17% -$42.9K 0.03% 678
2022
Q1 		$266K Sell
4,349
-923
-18% -$47.9K 0.06% 499
2021
Q4 		$276K Buy
+5,272
New +$221K 0.07% 422
2021
Q1 		– Sell
-10,453
Closed -$337K – 851
2020
Q4 		$337K Buy
+10,453
New +$275K 0.14% 272

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Y-Intercept (HK)'s ITCI Position: Q1 2025 in Review

Y-Intercept (HK) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 6,525 shares — an estimated $545K sold.

Y-Intercept (HK) first reported a position in ITCI in Q4 2020 and held it in 10 quarters. The position peaked at $5.21M in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Y-Intercept (HK) reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 6,525 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $545K.
  • Y-Intercept (HK) first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 10 quarters.
  • Y-Intercept (HK)'s Intra-Cellular Therapies Inc. position peaked at $5.21M in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Y-Intercept (HK)'s 13F filing for Q1 2025, filed 6 May 2025.